NASDAQ:MDCX Medicus Pharma (MDCX) Stock Price, News & Analysis $2.22 -0.23 (-9.39%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Medicus Pharma Stock (NASDAQ:MDCX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medicus Pharma alerts:Sign Up Key Stats Today's Range$2.19▼$2.4450-Day Range$1.96▼$3.4052-Week Range$1.80▼$8.94Volume590,547 shsAverage Volume411,232 shsMarket Capitalization$39.56 millionP/E RatioN/ADividend YieldN/APrice Target$23.50Consensus RatingStrong Buy Company Overview Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario. Read More Medicus Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreMDCX MarketRank™: Medicus Pharma scored higher than 37% of companies evaluated by MarketBeat, and ranked 702nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingMedicus Pharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMedicus Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Medicus Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Medicus Pharma are expected to decrease in the coming year, from ($1.14) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medicus Pharma is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medicus Pharma is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedicus Pharma has a P/B Ratio of 12.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MDCX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedicus Pharma does not currently pay a dividend.Dividend GrowthMedicus Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MDCX. News and Social Media2.2 / 5News Sentiment-0.10 News SentimentMedicus Pharma has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Medicus Pharma this week, compared to 2 articles on an average week.Search Interest14 people have searched for MDCX on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat Follows13 people have added Medicus Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 18% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medicus Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders11.20% of the stock of Medicus Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Medicus Pharma's insider trading history. Receive MDCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicus Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address MDCX Stock News HeadlinesMedicus Pharma Completes Equity Sales to YorkvilleAugust 22 at 8:21 PM | msn.comMedicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of ...August 21 at 9:33 AM | finance.yahoo.comOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from a $63,000 luxury… into a 90-cent mass production reality. It’s 400x stronger than steel, conducts electricity better than copper… and just saved 379 lives in a single plane crash.August 24 at 2:00 AM | True Market Insiders (Ad)Medicus Pharma Advances D-MNA Clinical Program and Expands Strategic PartnershipsAugust 21 at 8:51 AM | tipranks.comBiotech at a Pivotal Moment: Four Stocks Defining The Transformation (MDCX, IOBT, INSM, RNA)August 20, 2025 | theglobeandmail.comBiotech’s Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM, ENTA)August 19, 2025 | theglobeandmail.comQ3 EPS Forecast for Medicus Pharma Decreased by AnalystAugust 19, 2025 | americanbankingnews.comMedicus Pharma Ltd to Acquire Antev Ltd in Strategic Expansion MoveAugust 7, 2025 | theglobeandmail.comSee More Headlines MDCX Stock Analysis - Frequently Asked Questions How have MDCX shares performed this year? Medicus Pharma's stock was trading at $2.43 at the start of the year. Since then, MDCX shares have decreased by 8.6% and is now trading at $2.22. How were Medicus Pharma's earnings last quarter? Medicus Pharma Ltd (NASDAQ:MDCX) posted its earnings results on Monday, August, 11th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by $0.04. When did Medicus Pharma IPO? Medicus Pharma (MDCX) raised $4 million in an initial public offering (IPO) on Thursday, November 14th 2024. The company issued 1,000,000 shares at a price of $4.13 per share. Maxim Group LLC served as the underwriter for the IPO and Brookline Capital Markets was co-manager. Who are Medicus Pharma's major shareholders? Medicus Pharma's top institutional investors include Interchange Capital Partners LLC (11.69%), Guyasuta Investment Advisors Inc. (0.57%), SeaCrest Wealth Management LLC (0.34%) and May Hill Capital LLC (0.26%). View institutional ownership trends. How do I buy shares of Medicus Pharma? Shares of MDCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2025Today8/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MDCX Previous SymbolNASDAQ:MDCX CIK1997296 Webwww.medicuspharma.com Phone732-300-3046FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Medicus Pharma$23.50 High Price Target$27.00 Low Price Target$20.00 Potential Upside/Downside+958.6%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-549.30% Return on Assets-228.06% Debt Debt-to-Equity RatioN/A Current Ratio1.29 Quick Ratio1.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book12.33Miscellaneous Outstanding Shares17,820,000Free Float15,821,000Market Cap$39.56 million OptionableN/A BetaN/A 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:MDCX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.